
Federico Menapace, a former bridge engineer turned mental‑wellness advocate, survived the suicide of his mother and later healed through a psilocybin‑assisted session. Leveraging his MBA from Stanford and experience as COO of MAPS, he now challenges the profit‑driven mental‑health model exemplified by Spravato. Menapace is launching a public‑benefit corporation that pairs insurance‑reimbursed psychedelic treatments with group therapy to address root causes of suffering. His outsider, design‑thinking perspective aims to reconnect policy, science, and patient access in a fragmented industry.

Anthropic’s recent turmoil—losing a $200 million Pentagon contract, being flagged as a national‑security supply‑chain risk, yet seeing its Claude AI climb to the top of the App Store—frames a LinkedIn Live event at 10 AM PST. Eric Ries, author of *The Lean Startup*...

Plantible Foods has secured a landmark FDA “No Questions” letter for its Rubi Protein, the first isolated RuBisCO‑based protein recognized as safe for food use. The clearance removes regulatory barriers, allowing the ingredient to be incorporated into baked goods, beverages,...